Amit H. Thakore
Mr. Thakore is counsel in the Firm's Intellectual Property Practice Group. His practice is focused in the area of patent litigation, including lawsuits arising under the Hatch-Waxman Act and Biologics Price Competition and Innovation Act (BPCIA).
Mr. Thakore has also conducted a number of due diligence investigations for clients, including patent validity and infringement assessments in a variety of technical disciplines. He has also assisted clients with the prosecution of patent applications concerning biomedical devices.
Representation of Samsung Bioepis Co., Ltd. in BPCIA litigation concerning a biosimilar version of Herceptin® (trastuzumab); also represented Samsung Bioepis in related inter partes review proceedings at the Patent Trial and Appeal Board. Genentech, Inc. v. Samsung Bioepis Co., Ltd., 18-cv-1363 (D. Del.)
Representation of UCB Inc. in a patent infringement action brought by Apotex in which Apotex's patent was found unenforceable due to inequitable conduct. The district court’s holding was affirmed by the Federal Circuit. UCB was subsequently awarded over US $6 million in attorney fees, one of the largest such awards in a patent case at that time. Apotex, Inc. et al v. UCB, Inc. et al, 12-cv-60706 (S.D. Fla.).
Counsel to Pfizer in various inter partes review proceedings and related appeals concerning vaccine patents.
Counsel to Javelin and Hospira in Hatch-Waxman patent litigation in the District of Delaware concerning patents that cover DYLOJECT®, a nonsteroidal anti-inflammatory drug for intravenous administration.
Co-author, "Recent Developments in Pharmaceutical and Biotechnology Litigation," 2nd Annual Patent Law Institute (Volume Two), Practising Law Institute (2008)